Novo Nordisk Annual Report 2022 61Contents Introducing Novo Nordisk Strategic Aspirations Key risks Management Consolidated statements Additional information
Net sales – Business segments and geographical areas
Total International Operations Total North America Operations Total Novo Nordisk
net sales
Total IO EMEA China Rest of World Total NAO Of which the US
DKK million 2022 2021 2020 2022 2021 2020 2022 2021 2020 2022 2021 2020 2022 2021 2020 2022 2021 2020 2022 2021 2020
Diabetes and Obesity care segment:
Rybelsus
®
3,155 524 36 1,714 289 36 63 — — 1,378 235 — 8,144 4,314 1,837 8,011 4,243 1,826 11,299 4,838 1,873
Ozempic
®
17,369 8,856 3,634 10,417 6,393 3,112 2,196 303 10 4,756 2,160 512 42,381 24,849 17,577 38,750 23,168 16,650 59,750 33,705 21,211
Victoza
®
5,672 6,726 7,095 2,724 3,527 4,251 1,478 1,544 1,033 1,470 1,655 1,811 6,650 8,328 11,652 6,406 8,031 11,292 12,322 15,054 18,747
Total GLP-1 26,196 16,106 10,765 14,855 10,209 7,399 3,737 1,847 1,043 7,604 4,050 2,323 57,175 37,491 31,066 53,167 35,442 29,768 83,371 53,597 41,831
Long-acting insulin 11,403 11,074 9,959 7,157 6,729 6,451 1,636 2,080 1,471 2,610 2,265 2,037 5,338 6,990 8,480 4,685 6,412 7,962 16,741 18,064 18,439
– of which Tresiba
®
6,092 5,486 4,407 3,485 2,979 2,574 1,050 1,095 418 1,557 1,412 1,415 3,261 4,243 4,561 2,723 3,793 4,191 9,353 9,729 8,968
– of which Xultophy
®
2,400 2,135 1,789 1,716 1,693 1,605 45 3 1 639 439 183 409 522 655 399 512 642 2,809 2,657 2,444
– of which Levemir
®
2,911 3,453 3,763 1,956 2,057 2,272 541 982 1,052 414 414 439 1,668 2,225 3,264 1,563 2,107 3,129 4,579 5,678 7,027
Premix insulin 10,023 10,512 10,246 2,622 2,879 2,959 4,912 5,224 4,852 2,489 2,409 2,435 539 691 679 517 665 652 10,562 11,203 10,925
– of which Ryzodeg
®
2,889 1,711 1,291 495 392 321 1,218 283 39 1,176 1,036 931 — — — — — — 2,889 1,711 1,291
– of which NovoMix
®
7,134 8,801 8,955 2,127 2,487 2,638 3,694 4,941 4,813 1,313 1,373 1,504 539 691 679 517 665 652 7,673 9,492 9,634
Fast-acting insulin 10,826 10,903 10,808 6,456 6,454 6,584 1,942 2,288 2,075 2,428 2,161 2,149 6,637 6,784 7,505 6,247 6,357 7,101 17,463 17,687 18,313
– of which Fiasp
®
1,354 1,106 832 1,138 965 764 — — — 216 141 68 649 642 553 606 605 519 2,003 1,748 1,385
– of which NovoRapid
®
9,472 9,797 9,976 5,318 5,489 5,820 1,942 2,288 2,075 2,212 2,020 2,081 5,988 6,142 6,952 5,641 5,752 6,582 15,460 15,939 16,928
Human insulin 6,508 7,453 7,339 1,983 2,152 2,370 1,812 2,692 2,655 2,713 2,609 2,314 1,678 1,599 1,534 1,605 1,515 1,431 8,186 9,052 8,873
Total insulin 38,760 39,942 38,352 18,218 18,214 18,364 10,302 12,284 11,053 10,240 9,444 8,935 14,192 16,064 18,198 13,054 14,949 17,146 52,952 56,006 56,550
Other Diabetes care 2,428 2,644
2,946 717 713 725 1,181 1,432 1,546 530 499 675 797 950 1,085 660 806 943 3,225 3,594 4,031
Total Diabetes care 67,384 58,692 52,063 33,790 29,136 26,488 15,220 15,563 13,642 18,374 13,993 11,933 72,164 54,505 50,349 66,881 51,197 47,857 139,548 113,197 102,412
Wegovy
®
54 — — 54 — — — — — — — — 6,134 1,386 — 6,134 1,386 — 6,188 1,386 —
Saxenda
®
5,832 3,117 2,118 3,561 1,809 1,124 133 61 10 2,138 1,247 984 4,844 3,897 3,490 4,368 3,526 3,230 10,676 7,014 5,608
Total Obesity care 5,886 3,117 2,118 3,615 1,809 1,124 133 61 10 2,138 1,247 984 10,978 5,283 3,490 10,502 4,912 3,230 16,864 8,400 5,608
Diabetes and Obesity care total 73,270 61,809 54,181 37,405 30,945 27,612 15,353 15,624 13,652 20,512 15,240 12,917 83,142 59,788 53,839 77,383 56,109 51,087 156,412 121,597 108,020
Rare disease segment:
Rare blood disorders 6,671 5,784 5,708 3,795 3,712 3,579 604 222 361 2,272 1,850 1,768 5,035 4,433 3,954 4,710 4,170 3,675 11,706 10,217 9,662
– of which Haemophilia A 1,769 1,625 1,332 1,137 1,162 983 81 24 16 551 439 333 569 487 381 543 460 358 2,338 2,112 1,713
– of which Haemophilia B 479 400 306 294 268 199 13 4 — 172 128 107 280 237 212 152 102 86 759 637 518
– of which NovoSeven
®
4,335 3,673 3,996 2,311 2,225 2,352 510 194 345 1,514 1,254 1,299 3,973 3,548 3,207 3,811 3,461 3,089 8,308 7,221 7,203
Rare endocrine disorders 4,904 4,880 4,832 2,232 2,212 2,220 246 167 66 2,426 2,501 2,546 2,234 2,423 2,875 2,205 2,400 2,857 7,138 7,303 7,707
Other Rare disease 1,002 1,064 1,108 804 837 886 6 6 5 192 221 217 696 619 449 358 330 205 1,698 1,683 1,557
Rare disease total 12,577 11,728 11,648 6,831 6,761 6,685 856 395 432 4,890 4,572 4,531 7,965 7,475 7,278 7,273 6,900 6,737 20,542 19,203 18,926
Total sales by geographical area 85,847 73,537 65,829 44,236 37,706 34,297 16,209 16,019 14,084 25,402 19,812 17,448 91,107 67,263 61,117 84,656 63,009 57,824 176,954 140,800 126,946
Total sales growth as reported 16.7% 11.7% 6.9% 17.3% 9.9% 6.5% 1.2% 13.7% 9.7% 28.2% 13.5% 5.7% 35.4% 10.1% 1.1% 34.4% 9.0% 0.6% 25.7% 10.9% 4.0%